Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

CompletedOBSERVATIONAL
Enrollment

2,104

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2025

Conditions
Renal Anemia
Interventions
DRUG

Roxadustat

Oral

Trial Locations (47)

Unknown

Site JP00023, Aichi

Site JP00005, Akita

Site JP00002, Aomori

Site JP00012, Chiba

Site JP00038, Ehime

Site JP00018, Fukui

Site JP00040, Fukuoka

Site JP00007, Fukushima

Site JP00021, Gifu

Site JP00010, Gunma

Site JP00034, Hiroshima

Site JP00001, Hokkaido

Site JP00028, Hyōgo

Site JP00008, Ibaraki

Site JP00017, Ishikawa

Site JP00037, Kagawa

Site JP00046, Kagoshima

Site JP00014, Kanagawa

Site JP00039, Kochi

Site JP00043, Kumamoto

Site JP00026, Kyoto

Site JP00024, Mie

Site JP00004, Miyagi

Site JP00045, Miyazaki

Site JP00020, Nagano

Site JP00042, Nagasaki

Site JP00029, Nara

Site JP00015, Niigata

Site JP00003, Numakunai

Site JP00033, Okayama

Site JP00047, Okinawa

Site JP00027, Osaka

Site JP00044, Ōita

Site JP00041, Saga

Site JP00011, Saitama

Site JP00025, Shiga

Site JP00032, Shimane

Site JP00022, Shizuoka

Site JP00009, Tochigi

Site JP00036, Tokushima

Site JP00013, Tokyo

Site JP00031, Tottori

Site JP00016, Toyama

Site JP00030, Wakayama

Site JP00006, Yamagata

Site JP00035, Yamaguchi

Site JP00019, Yamanashi

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY